home / stock / mrns / mrns news


MRNS News and Press, Marinus Pharmaceuticals Inc.

Stock Information

Company Name: Marinus Pharmaceuticals Inc.
Stock Symbol: MRNS
Market: NASDAQ
Website: marinuspharma.com

Menu

MRNS MRNS Quote MRNS Short MRNS News MRNS Articles MRNS Message Board
Get MRNS Alerts

News, Short Squeeze, Breakout and More Instantly...

MRNS - Palisade Bio, Marinus Pharmaceuticals, Poseida Therapeutics among healthcare movers

2024-04-16 10:00:22 ET More on Health Care Select Sector SPDR XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run Shor...

MRNS - Overweight Recommendation Issued On MRNS By Cantor Fitzgerald

2024-04-16 08:15:04 ET Cantor Fitzgerald analyst issues OVERWEIGHT recommendation for MRNS on April 16, 2024 06:31AM ET. The previous analyst recommendation was Overweight. MRNS was trading at $1.3 at issue of the analyst recommendation. The overall analyst consensus : H...

MRNS - US Companies Moving the Markets, Evening edition
Mon, Apr 15, 2024 as of 4:00 pm ET

A look at the top 10 most actives in the United States PROSHARES TRUST (SQQQ) rose 5.1% to $11.44 on volume of 198,678,404 shares Trio Petroleum Corp. (TPET) rose 22.1% to $0.63 on volume of 179,140,668 shares Soligenix Inc. (SNGX) rose 21.7% to $0.47 on volume of 133,754,026 shares Sup...

MRNS - MRNS Price Target Alert: $3.00. Issued by RBC Capital

2024-04-15 14:00:04 ET Sector Perform from RBC Capital issued a price target of $3.00 for MRNS on 2024-04-15 12:55:00. The adjusted price target was set to $3.00. At the time of the announcement, MRNS was trading at $1.415. The overall price target consensus is at $9.00 ...

MRNS - BSGM, ENLV and WISA among mid-day movers

2024-04-15 12:47:11 ET More on Mid-day movers & stocks. Enlivex stock plunges 50% on mixed results from sepsis study WiSA Technologies to effect 1-for-150 reverse stock split Seeking Alpha’s Quant Rating on BioSig Technologies, Inc. Historical earn...

MRNS - Marinus plummets 78% as phase 3 interim analysis of ganaxolone disappoints

2024-04-15 11:00:02 ET More on Marinus Pharmaceuticals Marinus Pharmaceuticals, Inc. (MRNS) Q4 2023 Earnings Call Transcript Marinus Pharmaceuticals Q4 2023 Earnings Preview Seeking Alpha’s Quant Rating on Marinus Pharmaceuticals Historical earnings da...

MRNS - Marinus Pharmaceuticals, Cartesian Therapeutics, Adial Pharmaceuticals among healthcare movers

2024-04-15 10:00:31 ET More on Health Care Select Sector SPDR XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run Shor...

MRNS - US Companies Moving the Markets, Morning edition
Mon, Apr 15, 2024 as of 10.00 am ET

A look at the top 10 most actives in the United States Soligenix Inc. (SNGX) rose 127.5% to $0.8782 on volume of 62,157,057 shares Trio Petroleum Corp. (TPET) rose 8.0% to $0.5571 on volume of 48,902,033 shares Organovo Holdings Inc. (ONVO) rose 36.3% to $1.3769 on volume of 34,819,187 sh...

MRNS - NXPL, MGRM and OCX among pre-market losers

2024-04-15 08:21:07 ET More on Pre-market losers & stocks. OncoCyte Corporation (OCX) Q4 2023 Earnings Call Transcript Monogram Orthopaedics, Inc. (MGRM) Q4 2023 Earnings Call Transcript Monogram Orthopaedics, Inc. 2023 Q4 - Results - Earnings Call Presentation ...

MRNS - Marinus Pharmaceuticals Provides Update on the Phase 3 RAISE Trial and Reports Preliminary First Quarter 2024 Financial Results

Trial did not meet pre-defined stopping criteria at the interim analysis; Marinus has completed RAISE enrollment at approximately 100 patients with topline results expected summer 2024 Future development of IV ganaxolone in refractory status epilepticus to be assessed following review of ...

Next 10